Lenalidomide Glenmark

Lenalidomide, the active ingredient in Lenalidomide Glenmark, is an immunomodulatory drug (IMiD) presented as an oral tablet for oral use. It is indicated for the treatment of multiple myeloma and myelodysplastic syndromes with del(5q) in adult patients. The product complies with EU GMP standards and is intended for oncology practice in hospitals and specialized treatment centres.

GNH USA supplies Lenalidomide Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring reliable quality and regulatory compliance.

Lenalidomide is an immunomodulatory agent used in specific hematologic malignancies.

Multiple myeloma: improves disease control and prolongs progression‑free survival in adult patients. Myelodysplastic syndromes with del(5q): reduces transfusion dependence and improves hematologic parameters. Mantle cell lymphoma (relapsed/refractory): contributes to tumor response when combined with other therapies.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Fatigue - Neutropenia - Thrombocytopenia - Anemia - Diarrhea - Rash

Serious or Rare Side Effects: - Venous thromboembolism - Severe neutropenia - Severe thrombocytopenia - Secondary primary malignancies - Severe allergic reactions (anaphylaxis) - Liver toxicity (elevated transaminases)

When prescribing Lenalidomide, clinicians should observe several safety measures to minimize risk. - Monitor blood counts: perform regular complete blood count assessments to detect cytopenias. - Assess thrombotic risk: evaluate patient history and consider prophylactic anticoagulation when appropriate. - Evaluate renal function: adjust dosing in patients with impaired clearance. - Avoid pregnancy: ensure effective contraception for both male and female patients of reproductive potential. - Review concomitant medications: check for drugs that may increase toxicity or reduce efficacy. - Store at ambient temperature: keep below 25 °C in the original container, protected from moisture.

Lenalidomide interacts with several medicines; awareness of major and moderate interactions helps guide safe co‑administration.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase lenalidomide exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Anticoagulants (e.g., warfarin): increased risk of bleeding.

Moderate Interactions (Monitor Closely): - NSAIDs: may enhance bleeding tendency. - Digoxin: may increase serum levels. - CYP3A4 substrate drugs (e.g., midazolam): may have altered concentrations.